{
    "clinical_study": {
        "@rank": "95922", 
        "arm_group": [
            {
                "arm_group_label": "L-pantoprazole sodium", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Panmeilu", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and Efficacy of L- Pantoprazole sodium\n      to treat upper gastrointestinal ulcer bleeding."
        }, 
        "brief_title": "Efficacy and Safety of L-Pantoprazole Sodium Injection to Treat Upper Gastrointestinal Ulcer Bleeding", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Bleeding Gastric Ulcer", 
            "Bleeding Duodenal Ulcer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Duodenal Ulcer", 
                "Hemorrhage", 
                "Stomach Ulcer", 
                "Ulcer", 
                "Gastrointestinal Hemorrhage"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age: 18-65 years, gender:both.\n\n          2. Patients whose Forrest classification were in \u2160 b-\u2161 c were diagnosed with\n             non-variceal duodenal and / or gastric ulcer bleeding  by endoscopy within 24 hours\n             and patients manifested  vomiting and / or black stools and other symptoms of upper\n             gastrointestinal bleeding.\n\n          3. Patients were diagnosed with upper gastrointestinal bleeding mild to moderate;\n\n          4. Informed consent granted.\n\n          5. Patients agreed to take medicine and assess.\n\n        Exclusion Criteria:\n\n          1. Patients were diagnosed with upper gastrointestinal bleeding  by endoscopy caused by\n             esophageal varices and portal hypertensive gastropathy, Mallory-Weiss syndrome,\n             dieulafoy disease.\n\n          2. Pregnant women or breastfeeding women.\n\n          3. Patients who had undergone surgery because of ulcer complications or gastrectomy,\n             gastrointestinal anastomosis within 30 days before the trial.\n\n          4. Patients were diagnosed with gastrinoma or gastric malignancy.\n\n          5. Patients had other associated complications, which may affect the efficacy.\n\n          6. Patients who like alcohol abuse, drug addicts or others which are not suitable for\n             drug trials.\n\n          7. Patients who were allergic to any ingredient of any PPI and allergies.\n\n          8. Patients  diagnosed with small vessel spurting who had to undergo endoscopic\n             hemostasis or surgery or severe gastrointestinal bleeding.\n\n          9. Patients suffering from serious heart, brain, lung, liver, kidney disease or severe\n             hypertension.\n\n         10. Patients who had coagulopathy, whose PT wasmore three seconds than normal controls,\n             whose APTT> 1.5 times the upper limit of normal or low-dose heparin treatment.\n\n         11. Patients whose systolic blood pressure less than 90mmHg or lower > 30mmHg than the\n             baseline systolic blood pressure,  pulse pressure less than 20mmHg, hematocrit less\n             than 20%.\n\n         12. Patients who participated in other clinical trials within three months before this\n             trial.\n\n         13. Patients who need to use other drugs which may affect the trial during the trial or a\n             week before the trial.\n\n         14. Patients who were considered unsuitable for selected candidates."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "272", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02108756", 
            "org_study_id": "2014-CTTQ-SPAN"
        }, 
        "intervention": [
            {
                "arm_group_label": "L-pantoprazole sodium", 
                "description": "2 injection L-pantoprazole sodium (40mg), Bid", 
                "intervention_name": "L-pantoprazole sodium", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Panmeilu", 
                "description": "An injection Panmeilu (80 mg) + 1 branch placebo, Bid;", 
                "intervention_name": "Panmeilu", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Pantoprazole"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 8, 2014", 
        "location": {
            "contact": {
                "email": "hanying@fmmu.edu.cn", 
                "last_name": "Han Ying, doctor", 
                "phone": "13991963770"
            }, 
            "facility": {
                "address": {
                    "city": "Xi'an", 
                    "country": "China", 
                    "state": "Shaanxi", 
                    "zip": "710032"
                }, 
                "name": "The first affiliated hospital of the Fourth Military Medical University"
            }, 
            "investigator": [
                {
                    "last_name": "Fan Dai ming, doctor", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Wu Kai chun, doctor", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Han Ying, doctor", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "hanying@fmmu.edu.cn", 
            "last_name": "Han Ying, doctor", 
            "phone": "13991963770"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Hemostatic success rate", 
            "safety_issue": "No", 
            "time_frame": "6 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02108756"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}